FDA seeks public input on the impact of patient-focused drug development meetings
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
FDA is opening a public docket to collect real-world examples of how patient-focused drug development meetings have shaped drug research, clinical trial design, patient advocacy, community engagement, clinical practice, and related work. Patient groups, drug developers, healthcare providers, researchers, caregivers, and advocates can submit comments by June 30, 2026. Comments filed online will be public, so organizations should avoid including private medical details, personal identifiers, or confidential business information unless they use the paper confidential submission process.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Creates a public docket for examples of the impact of FDA-led and externally led patient-focused drug development meetings
- Requests input on effects on patient engagement, research gaps, product development, trial design, endpoints, partnerships, and clinical practice
- Sets a June 30, 2026 deadline for electronic or written comments and gives instructions for confidential submissions
Obligations
What this law requires
Submit any electronic or written comments on the notice by June 30, 2026; late comments will not be considered.
Include Docket No. FDA-2026-N-3947 in all submissions for the notice titled “Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments.”
Submit electronic comments through the Federal eRulemaking Portal at https://www.regulations.gov and follow the portal’s submission instructions.
Do not include confidential information, private medical information, Social Security numbers, personal identifiers, or confidential business information in electronic comments unless the submitter is willing for that information to be posted publicly unchanged.
Submit written or paper comments by mail, hand delivery, or courier to Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852.